FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London

About this trial

FECD-TRACE is an integral component of a large research program dedicated to Fuchs Endothelial Corneal Dystrophy (FECD) in the United Kingdom. This longitudinal, observational study aims to comprehensively characterize a cohort of younger research participants who have a genetic predisposition to developing FECD. By utilizing advanced anterior segment imaging techniques, the study will monitor these individuals over a span of several years, capturing phenotypic changes that reflect the progression of the disease. Concurrently, genetic biomarkers will be examined to establish correlations with the observed phenotypic changes. The primary objective of FECD-TRACE is to enhance our understanding of the intricate genetic mechanisms underlying FECD and establish connections between these genetic findings and clinical outcomes. Ultimately, this research strives to facilitate the development of personalized care approaches for individuals affected by FECD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Willing and able to provide informed consent for participation in the study

Willing to attend scheduled study visits and undergo a clinical examination

Willing to donate blood/saliva samples

Fulfil the abovementioned cohort criteria

Disqualifiers

Presence of a secondary cause for corneal endothelial dysfunction or oedema

Presence of clinically evident corneal oedema

History of concurrent corneal diseases

History of corneal surgeries, including corneal transplantation

Trial population

Participants meeting the recruitment criteria across multiple sites will be enrolled

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Clinical phenotyping

    Diagnostic test

    * Visual acuity assessment * Contrast sensitivity evaluation * Slit-lamp photography * Specular microscopy * Scheimpflug tomography * Anterior segment optical coherence tomography * In vivo confocal microscopy * Spatio-temporal optical coherence tomography

  • CTG18.1 Expansion Status Genotyping

    Genetic

    Genotyping for trinucleotide repeat in the TCF4 gene (CTG18.1) and other genetic biomarkers using blood or saliva derived genomic DNA. This includes: * Short tandem repeat - PCR * Triplet-repeat primed - PCR * Genome-wide single nucleotide polymorphism genotyping * Ultra-deep locus-specific next-generation sequencing

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: Pre-symptomatic FECD cohort2 interventions
Group B: Control cohort2 interventions

Trial outcomes

Primary outcomes

1

Endothelial cell density measurement (cells/mm2)

Specular Microscopy - Endothelial cell density.

Time frame
Baseline
2

CTG18.1 allele length (in number)

Polymerase Chain Reaction (PCR) will be performed from DNA (blood sample)

Time frame
Baseline
3

Detection of guttata (cells/mm2)

In Vivo Confocal Microscopy (IVCM) - Detection of guttata

Time frame
Baseline
4

Corneal thickness (in micrometers)

Anterior Segment Optical Coherence Tomography (AS-OCT) - Corneal thickness

Time frame
Baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.